Product How it works Pricing Blog FAQ About Contact
Cogent Biosciences

Cogent Biosciences (NASDAQ: COGT) net income

Cogent Biosciences reported a net loss of $328.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $255.9m. Earnings per share were −$2.16.

Cogent Biosciences's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.

Net income, in millions of US dollars-25.52017-34.52018-31.82019-74.82020-72.32021-140.22022-192.42023-255.92024-328.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$328.9m——−$2.16
2024−$255.9m——−$1.94
2023−$192.4m——−$2.42
2022−$140.2m——−$2.39
2021−$72.3m——−$1.87
2020−$74.8m—−950.4%—
2019−$31.8m—−141.5%—
2018−$34.5m—−354.8%—
2017−$25.5m—−304.9%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Cogent Biosciences net income compared with its sector

By net income for its latest fiscal year, Cogent Biosciences ranks 453rd of the 501 US health care companies with a page on Celsmar.

RankCompanyNet incomeNet margin
451stGinkgo Bioworks−$312.8m−183.8%
452ndReplimune Group−$313.9m—
453rdCogent Biosciences−$328.9m—
454thViridian Therapeutics−$342.6m−483.6%
455thXenon Pharmaceuticals−$345.9m−4,612.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Cogent Biosciences

How much did Cogent Biosciences earn in fiscal 2025?
Cogent Biosciences reported a net loss of $328.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $255.9m.
What are the earnings per share of Cogent Biosciences?
They were −$2.16 in fiscal 2025, compared with −$1.94 in fiscal 2024.
Where does Cogent Biosciences rank in its sector by net income?
It ranks 453rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Cogent Biosciences come from?
From the annual report (Form 10-K) that Cogent Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Cogent Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Cogent Biosciences: the Cogent Biosciences page · annual accounts · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.